{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:45:40Z","timestamp":1768812340111,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.omto.2022.02.014","type":"journal-article","created":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T09:49:01Z","timestamp":1645350541000},"page":"788-798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Anticancer effects of a single intramuscular dose of a minicircle DNA vector expressing anti-CD3\/CD20 in a xenograft mouse model"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-7631","authenticated-orcid":false,"given":"Xiaojuan","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-3213","authenticated-orcid":false,"given":"Xiaohu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7063-3802","authenticated-orcid":false,"given":"Cheng-Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-3243","authenticated-orcid":false,"given":"Zhi-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2022.02.014_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.omto.2022.02.014_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/imr.12393","article-title":"Harnessing T\u00a0cells to fight cancer with BiTE(R) antibody constructs--past developments and future directions","volume":"270","author":"Klinger","year":"2016","journal-title":"Immunological Rev."},{"key":"10.1016\/j.omto.2022.02.014_bib3","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omto.2022.02.014_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/cts.12877","article-title":"Quantitative clinical pharmacology of t-cell engaging bispecifics: current perspectives and opportunities","volume":"14","author":"Morcos","year":"2021","journal-title":"Cts-Clinical Translational Sci."},{"key":"10.1016\/j.omto.2022.02.014_bib5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T\u00a0cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2022.02.014_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omto.2022.02.014_bib7","first-page":"5","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"Clin. Pharmacol. : Adv. Appl."},{"key":"10.1016\/j.omto.2022.02.014_bib8","first-page":"25","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nature reviews"},{"key":"10.1016\/j.omto.2022.02.014_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1525-0016(03)00168-0","article-title":"Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in\u00a0vivo","volume":"8","author":"Chen","year":"2003","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.omto.2022.02.014_bib10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nbt.1708","article-title":"A robust system for production of minicircle DNA vectors","volume":"28","author":"Kay","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2022.02.014_bib11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/hum.2016.122","article-title":"Treatment of human B-Cell lymphomas\u00a0using minicircle DNA vector expressing anti-CD3\/CD20 in a mouse model","volume":"28","author":"Pang","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2022.02.014_bib12","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.02.014_bib13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T\u00a0cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2022.02.014_bib14","article-title":"Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1\/PDL1 blockade and HER2 inhibition","author":"Gu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.omto.2022.02.014_bib15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.gt.3302827","article-title":"Variability of naked DNA expression after direct local injection: the influence of the injection speed","volume":"13","author":"Andre","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2022.02.014_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/7895","article-title":"Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene","volume":"17","author":"Blezinger","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2022.02.014_bib17","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1161\/CIRCULATIONAHA.108.841155","article-title":"Novel minicircle vector for gene therapy in murine myocardial infarction","volume":"120","author":"Huang","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.omto.2022.02.014_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.omto.2022.02.014_bib19","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.02.014_bib20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T\u00a0cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.omto.2022.02.014_bib21","first-page":"2625","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia (vol 131, pg 1522, 2018)","volume":"133","author":"Gokbuget","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.02.014_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1016\/j.omto.2022.02.014_bib23","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Scientific Rep."},{"key":"10.1016\/j.omto.2022.02.014_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/sj.mt.6300399","article-title":"Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation","volume":"16","author":"Chen","year":"2008","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.omto.2022.02.014_bib25","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.02.014_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T\u00a0cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2022.02.014_bib27","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of\u00a0anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J.\u00a0Clin. Oncol. : official\u00a0J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.omto.2022.02.014_bib28","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T\u00a0cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522000316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522000316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:28:12Z","timestamp":1762496892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770522000316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"alternative-id":["S2372770522000316"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2022.02.014","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer effects of a single intramuscular dose of a minicircle DNA vector expressing anti-CD3\/CD20 in a xenograft mouse model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2022.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}